BiTE-ing into Prostate Cancer with Bispecific T-cell Engagers.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33707179.
- Also identified by DOI 10.1158/1078-0432.CCR-21-0355 and PMC identifier 8127346.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Targeting prostate-specific membrane antigen (PSMA) has important therapeutic ramifications, more recently including immune oncology. Data were recently presented on the preclinical efficacy of a half-life extended bispecific T-cell engager, AMG 160, which binds PSMA and CD3 to induce T-cell-driven cytolytic activity against prostate cancer.<i>See related article by Deegen et al., p. 2928</i>.
Medical subject headings
- Antibodies, Bispecific
- Prostatic Neoplasms